These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 34803506)
1. MAD2B-mediated cell cycle reentry of podocytes is involved in the pathogenesis of FSGS. Bao D; Su H; Lei CT; Tang H; Ye C; Xiong W; He FF; Lin JH; Hammes HP; Zhang C Int J Biol Sci; 2021; 17(15):4396-4408. PubMed ID: 34803506 [No Abstract] [Full Text] [Related]
2. MAD2B contributes to podocyte injury of diabetic nephropathy via inducing cyclin B1 and Skp2 accumulation. Su H; Wan Q; Tian XJ; He FF; Gao P; Tang H; Ye C; Fan D; Chen S; Wang YM; Meng XF; Zhang C Am J Physiol Renal Physiol; 2015 Apr; 308(7):F728-36. PubMed ID: 25651564 [TBL] [Abstract][Full Text] [Related]
3. CDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo. Marshall CB; Krofft RD; Pippin JW; Shankland SJ Am J Physiol Renal Physiol; 2010 May; 298(5):F1140-51. PubMed ID: 20130121 [TBL] [Abstract][Full Text] [Related]
4. MAD2B promotes podocyte injury through regulating Numb-dependent Notch 1 pathway in diabetic nephropathy. Li MR; Lei CT; Tang H; Yin XJ; Hao Z; Qiu Y; Xie YR; Zeng JY; Su H; Zhang C Int J Biol Sci; 2022; 18(5):1896-1911. PubMed ID: 35342338 [No Abstract] [Full Text] [Related]
5. Btg2 Promotes Focal Segmental Glomerulosclerosis via Smad3-Dependent Podocyte-Mesenchymal Transition. Dan Hu Q; Wang HL; Liu J; He T; Tan RZ; Zhang Q; Su HW; Kantawong F; Lan HY; Wang L Adv Sci (Weinh); 2023 Nov; 10(32):e2304360. PubMed ID: 37749872 [TBL] [Abstract][Full Text] [Related]
6. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats. Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165 [TBL] [Abstract][Full Text] [Related]
7. Angiopoietin-like-3 knockout protects against glomerulosclerosis in murine adriamycin-induced nephropathy by attenuating podocyte loss. Dai R; Liu H; Han X; Liu J; Zhai Y; Rao J; Shen Q; Xu H BMC Nephrol; 2019 May; 20(1):185. PubMed ID: 31126248 [TBL] [Abstract][Full Text] [Related]
9. Fibrinogen links podocyte injury with Toll-like receptor 4 and is associated with disease activity in FSGS patients. Wang H; Zheng C; Xu X; Zhao Y; Lu Y; Liu Z Nephrology (Carlton); 2018 May; 23(5):418-429. PubMed ID: 28407405 [TBL] [Abstract][Full Text] [Related]
10. Protective Role of the M-Sec-Tunneling Nanotube System in Podocytes. Barutta F; Kimura S; Hase K; Bellini S; Corbetta B; Corbelli A; Fiordaliso F; Barreca A; Papotti MG; Ghiggeri GM; Salvidio G; Roccatello D; Audrito V; Deaglio S; Gambino R; Bruno S; Camussi G; Martini M; Hirsch E; Durazzo M; Ohno H; Gruden G J Am Soc Nephrol; 2021 May; 32(5):1114-1130. PubMed ID: 33722931 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type-2-receptor stimulation ameliorates focal and segmental glomerulosclerosis in mice. Liao MC; Miyata KN; Chang SY; Zhao XP; Lo CS; El-Mortada MA; Peng J; Chenier I; Yamashita M; Ingelfinger JR; Chan JSD; Zhang SL Clin Sci (Lond); 2022 May; 136(10):715-731. PubMed ID: 35502764 [TBL] [Abstract][Full Text] [Related]
12. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling. Qiao Y; Wang P; Chang M; Chen B; Ge Y; Malhotra DK; Dworkin LD; Gong R Clin Sci (Lond); 2020 Apr; 134(7):695-710. PubMed ID: 32167144 [TBL] [Abstract][Full Text] [Related]
13. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics. Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981 [TBL] [Abstract][Full Text] [Related]
14. Asparagine endopeptidase protects podocytes in adriamycin-induced nephropathy by regulating actin dynamics through cleaving transgelin. Qiu Y; Lei C; Zeng J; Xie Y; Cao Y; Yuan Q; Su H; Zhang Z; Zhang C Mol Ther; 2023 Nov; 31(11):3337-3354. PubMed ID: 37689970 [TBL] [Abstract][Full Text] [Related]
15. Activation of necroptosis pathway in podocyte contributes to the pathogenesis of focal segmental glomerular sclerosis. Hu H; Li M; Chen B; Guo C; Yang N Clin Exp Nephrol; 2022 Nov; 26(11):1055-1066. PubMed ID: 35925422 [TBL] [Abstract][Full Text] [Related]
16. Blocking ribosomal protein S6 phosphorylation inhibits podocyte hypertrophy and focal segmental glomerulosclerosis. Li F; Fang Y; Zhuang Q; Cheng M; Moronge D; Jue H; Meyuhas O; Ding X; Zhang Z; Chen JK; Wu H Kidney Int; 2022 Jul; 102(1):121-135. PubMed ID: 35483522 [TBL] [Abstract][Full Text] [Related]
17. Genetic podocyte lineage reveals progressive podocytopenia with parietal cell hyperplasia in a murine model of cellular/collapsing focal segmental glomerulosclerosis. Suzuki T; Matsusaka T; Nakayama M; Asano T; Watanabe T; Ichikawa I; Nagata M Am J Pathol; 2009 May; 174(5):1675-82. PubMed ID: 19359523 [TBL] [Abstract][Full Text] [Related]
18. Cell-cycle regulatory proteins in the podocyte in collapsing glomerulopathy in children. Srivastava T; Garola RE; Singh HK Kidney Int; 2006 Aug; 70(3):529-35. PubMed ID: 16775597 [TBL] [Abstract][Full Text] [Related]
19. SRGAP1 Controls Small Rho GTPases To Regulate Podocyte Foot Process Maintenance. Rogg M; Maier JI; Dotzauer R; Artelt N; Kretz O; Helmstädter M; Abed A; Sammarco A; Sigle A; Sellung D; Dinse P; Reiche K; Yasuda-Yamahara M; Biniossek ML; Walz G; Werner M; Endlich N; Schilling O; Huber TB; Schell C J Am Soc Nephrol; 2021 Mar; 32(3):563-579. PubMed ID: 33514561 [TBL] [Abstract][Full Text] [Related]